Jefferies Maintains Buy on Nurix Therapeutics, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $41 to $45.